ACHV

Achieve Life Sciences, Inc.

NasdaqCMUSDEQUITY DELAYED

8.08

▲ 0.06 (0.75%)

MARKET · —

Price

Open

8.18

Prev close

8.02

Day high

8.19

Day low

7.90

Volume

1.06M

Market cap

—

P/E (TTM)

—

52W range

2.62 – 8.61

Trailing performance

Price return · vs SPY

Returnvs SPY

+5.27% +6.6%

+29.50% +25.8%

+73.70% +70.6%

+87.12% +76.1%

YTD

+60.76% +48.5%

+209.69% +189.7%

+61.09% -13.1%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

7.45

+8.41% from price

SMA 20

6.92

+15.43% from price

SMA 50

6.35

+25.82% from price

SMA 100

5.44

+48.58% from price

SMA 200

4.97

+60.88% from price

EMA 12

7.45

+8.45% from price

EMA 26

6.95

+16.18% from price

EMA 50

6.44

+25.37% from price

RSI (14)

68.4

Neutral

MACD (12,26,9)

0.50

Hist 0.13

ATR (14)

0.41

5.08% of price

Realised vol 30D

58.0%

Annualised

Bollinger upper

8.30

20, 2σ

Bollinger lower

5.55

20, 2σ

50 / 200 cross

Golden

6.35 vs 4.97

Trend bias

Above 200

+60.88%

Risk profile

Daily returns · 1Y window

Beta vs SPY

1.98

More volatile than market

Correlation to SPY

0.28

Largely independent

Realised vol 30D

58.0%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-54.5%

Peak to trough

Max drawdown 5Y

-80.1%

Peak to trough

ATR 14

0.41

5.08% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 8.08

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

ACHV · links out to the publisher

ACHV: Looking Ahead to Resubmission Zacks Small Cap Research · 4d ago Achieve Life Sciences' Cytisinicline to Unlock $760 Million Market Opportunity in Smoking Cessation, Morgan Stanley Says MT Newswires · 9d ago Morgan Stanley Initiates Achieve Life Sciences at Overweight, With $13 Price Target MT Newswires · 9d ago Achieve Life Sciences Stock Has Nearly Tripled in the Last Year. Now It Just Needs to Turn a Profit. Barchart · 10d ago Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates GlobeNewswire · 11d ago Achieve Life Sciences Appoints Ronald Dadino and Gloria Cosgrove to Lead CMC, Supply Chain, and Quality GlobeNewswire · 19d ago Achieve Life Sciences Announced Granting of New Hire Inducement Awards GlobeNewswire · 22d ago Achieve Life Sciences Stockholders Weigh Board Slate, Share Increase at Annual Meeting MarketBeat · 44d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.